3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
27
Lymphoma, Non-Hodgkin
24
Leukemia, Lymphocytic, Chronic, B-Cell
24
Lymphoma, Mantle-Cell
23
Lymphoma, Follicular
17
Lymphoma, Large B-Cell, Diffuse
15
Multiple Myeloma
14
Recurrence
13
Hodgkin Disease
12
Lymphoma, B-Cell, Marginal Zone
7
Leukemia
7
Waldenstrom Macroglobulinemia
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
4
Neoplasms
4
Leukemia, B-Cell
4
Hematologic Neoplasms
4
Myeloproliferative Disorders
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, B-Cell
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphoid
3
Small Cell Lung Carcinoma
2
Leukemia, Biphenotypic, Acute
2
Burkitt Lymphoma
2
Sezary Syndrome
1
Sarcoma
1
Renal Insufficiency, Chronic
1
Interventions
Cyclophosphamide
5
blinatumomab
4
Rituximab
3
Brentuximab Vedotin
3
fludarabine phosphate
2
fludarabine
2
dacetuzumab
2
cobomarsen
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Ifosfamide
2
Everolimus
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
Busulfan
2
sepantronium
1
pomalidomide
1
pembrolizumab
1
Vorinostat
1
DTRMWXHS-12
1
Bone Marrow Transplantation
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphatic Diseases
×
Bendamustine Hydrochloride
×
Clear all
NCT02499627
2021-05-27
FIL-BBV
Fondazione Italiana Linfomi - ETS
Phase 2
Terminated
43 enrolled